|
Cilengitide for PSA-Only Progressive Prostate Cancer
Untitled Document
Name of the Trial
Phase II Study of Cilengitide in Patients with Nonmetastatic Androgen-Independent
Prostate Cancer (CCUM-2004-045). See the protocol
summary.
Principal Investigator
 |
Dr. Maha Hussain
Principal Investigator |
Dr. Maha Hussain, University of Michigan Comprehensive Cancer Center.
Why This Trial Is Important
Prostate cancer usually responds initially to treatment that reduces the level
of male hormones in the body (antiandrogen therapy). However, most prostate
cancers eventually continue to grow despite hormone deprivation (androgen-independent
prostate cancer).
Measuring the level of prostate-specific antigen (PSA) in the blood is often
used to determine the response of prostate cancer to treatment. A rising PSA
level may indicate that active cancer cells remain in the body despite previous
treatments to remove or destroy them. Often, a rising PSA level is the only
signal that prostate cancer is still growing (PSA-only progression).
In this trial, men with PSA-only progression despite antiandrogen therapy will
be treated with a drug called cilengitide. Cilengitide blocks
receptor proteins
called integrins on the surface of prostate cancer cells that may play a role
in the ability of these cells to enter and exit the bloodstream, attach at potential
sites of metastasis, and promote the formation of new blood vessels (angiogenesis).
PSA level stabilization or decline would indicate that cilengitide can help
control prostate cancer growth in these patients.
"Men with this stage of advanced prostate cancer are incurable and no
standard treatment exists," said Dr. Hussain. "Our hope is that cilengitide
can help contain micrometastatic cancer
cells by preventing their spread and
adhesion to bone, which is the most common site of prostate cancer metastasis,
and by stopping their potential to establish new blood vessels."
Contact Information
This trial is no longer accepting patients. To locate other clinical trials for prostate cancer, search the NCI database of clinical trials or call the NCI Cancer Information Service at 1-800-4-CANCER
(1-800-422-6237). The call is toll free and confidential.
Back to Top |
